Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000935
Chunk: 27

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 27
---
, no other approvals or consents of the Board
of Directors, any authorized committee thereof, or shareholders (except as provided in this Agreement) is necessary under applicable laws
and the Articles of Association (as defined below) to authorize the execution and delivery of the Transaction Documents or any of the
transactions contemplated thereby, including, but not limited to, the allotment of the Purchase Shares and, if applicable, the Commitment
Shares.

(c) .
As of the Execution Date, the authorized share capital of the Company is set forth on Section 4(c) of the Disclosure Schedule. Except
as disclosed in the SEC Documents (as defined below) or in Section 4(c) of the Disclosure Schedule, (i) none of the Company’s share
capital is subject to preemptive rights or any other similar rights or any liens or encumbrances suffered or permitted by the Company,
(ii) there are no outstanding debt securities, (iii) there are no outstanding options, warrants, scrip, rights to subscribe to, calls
or commitments of any character whatsoever relating to, or securities or rights convertible into, any share capital of the Company or
any of its Subsidiaries, or contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries is
or may become bound to issue additional share capital of the Company or any of its Subsidiaries or options, warrants, scrip, rights to
subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, any share capital
of the Company or any of its Subsidiaries, (iv) there are no agreements or arrangements under which the Company or any of its Subsidiaries
is obligated to register the sale of any of their securities under the Securities Act (except the Registration Rights Agreement), (v)
there are no outstanding securities or instruments of the Company or any of its Subsidiaries which contain any redemption or similar provisions,
and there are no contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become
bound to redeem a security of the Company or any of its Subsidiaries, (vi) there are no securities or instruments containing anti-dilution
or similar provisions that will be triggered by the issuance of the Securities as described in this Agreement and (vii) the Company does
not have any share appreciation rights or “phantom share” plans or agreements or any